OKUR
Reneo Pharmaceuticals Inc - Class A (OKUR)
Healthcare • NASDAQ • $2.15+2.38%
- Symbol
- OKUR
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $2.15
- Daily Change
- +2.38%
- Market Cap
- $85.04M
- Trailing P/E
- N/A
- Forward P/E
- -1.38
- 52W High
- $5.38
- 52W Low
- $2.01
- Analyst Target
- $15.50
- Dividend Yield
- 0.00%
- Beta
- 0.75
OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers and other diseases. Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3-kinase alpha (PI3Ka) harboring the H1047R mutation that is in Phase 1 clinical trial for the treatment of solid tumors, including breast cancer. The company was founded in 2011 and is headquartered in Boulder, Colorado.
Company websiteResearch OKUR on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.